Volume 11, Issue 4 (Nov 2023)
Res Mol Med (RMM) 2023, 11(4): 227-234 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Mojarad-Jabali S, Molavipordanjani S. Clinical Application of Actinium-225 Radiopharmaceuticals in Targeted Alpha Therapy. Res Mol Med (RMM) 2023; 11 (4) :227-234
URL: http://rmm.mazums.ac.ir/article-1-553-en.html
URL: http://rmm.mazums.ac.ir/article-1-553-en.html
1- 1Pharmaceutical Sciences Research Center, Hemoglobinopathy Institute, Mazandaran University of Medical Sciences, Sari, Iran
2- 1Pharmaceutical Sciences Research Center, Hemoglobinopathy Institute, Mazandaran University of Medical Sciences, Sari, Iran ,sajjad.molavi@gmail.com
2- 1Pharmaceutical Sciences Research Center, Hemoglobinopathy Institute, Mazandaran University of Medical Sciences, Sari, Iran ,
Abstract: (945 Views)
Among the vast variety of radionuclides available, a handful of them possess proper features for targeted alpha therapy (TAT). TAT holds the promise of exceeding the effectiveness of conventional radiotherapy methods. Actinium-225 is considered to be an outstanding isotope for TAT in the management of cancer due to its half-life, which enables sustained delivery at the tumor site. This review covers the clinical applications of actinium-225 radiopharmaceuticals.
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-By-NC), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Contact Information
